Clinical Trials

Search for trials
Clinical Trial
  • Status: Not yet recruiting
  • Phase: Phase 2/Phase 3
  • Intervention Type: Other, Drug, Biological, Radiation
  • Participants: 100
  • Start Date: January 6, 2022
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Clinical Trial
  • Status: Recruiting
  • Participants: 36
  • Start Date: January 1, 2022
Immunogenicity and Safety of Pneumococcal Vaccination in Patients Treated With Immune Checkpoint Inhibitors
Search for trials
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1/Phase 2
  • Intervention Type: Drug, Biological
  • Participants: 18
  • Start Date: December 13, 2021
ATTAMAGE-A1.: Phase I/II Study of Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity MAGE-A1-Specific T-Cell Receptor (TCR) Combined With Atezolizumab in Patients With Metastatic MAGE-A1 Expressing Cancer
Clinical Trial
  • Status: Not yet recruiting
  • Phase: Phase 3
  • Intervention Type: Biological, Drug
  • Participants: 600
  • Start Date: December 10, 2021
A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met+, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
Clinical Trial
  • Status: Not yet recruiting
  • Phase: Phase 1/Phase 2
  • Intervention Type: Drug
  • Participants: 25
  • Start Date: December 2021
CAFs (Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC): a Phase I/II Study
Clinical Trial
  • Status: Not yet recruiting
  • Intervention Type: Drug
  • Participants: 69
  • Start Date: December 2021
An Observational Study of Afatinib 30 mg Daily in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring Common EGFR Mutations Treated With Afatinib
Clinical Trial
  • Status: Not yet recruiting
  • Phase: Phase 2
  • Intervention Type: Biological
  • Participants: 55
  • Start Date: November 5, 2021
A Phase II Study to Assess the Safety and Efficacy of Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
Clinical Trial
  • Status: Not yet recruiting
  • Phase: Phase 3
  • Intervention Type: Drug
  • Participants: 170
  • Start Date: October 31, 2021
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
Clinical Trial
  • Status: Not yet recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 52
  • Start Date: October 15, 2021
Efficacy and Safety of Aumolertinib in the Adjuvant Treatment of Resectable Stage IA Non-small Cell Lung Cancer With Solid and/or Micropapillary Component EGFR-sensitive Mutations: a Multi-center, Single-arm Clinical Trial
Clinical Trial
  • Status: Not yet recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 38
  • Start Date: September 30, 2021
Phase II Trial of Neoadjuvant and Adjuvant Capmatinib in Participants With Stages IB-IIIA, N2 and Selected IIIB (T3N2 or T4N2) NSCLC With MET Exon 14 Skipping Mutation or High MET Amplification (Geometry-N)
Clinical Trial
  • Status: Not yet recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 170
  • Start Date: September 13, 2021
A Phase 2, Multicenter, Open-label Study of Sotorasib (AMG 510) in Subjects With Stage IV NSCLC Whose Tumors Harbor a KRAS G12C Mutation in Need of First-line Treatment (CodeBreaK 201)
Clinical Trial
  • Status: Not yet recruiting
  • Phase: Early Phase 1
  • Intervention Type: Other
  • Participants: 50
  • Start Date: September 10, 2021
Collection of Peripheral Blood and Lung Lesion Samples From Participants With Suspected Lung Cancer to Examine the Potential of Bronchoscopic Biopsies to Assess Non-small Cell Lung Cancer (NSCLC) Tumor Immune Subtypes and Related Biomarkers
Showing 1-12 of 1585